A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases
Article first published online: 20 DEC 2005
Volume 48, Issue 2, pages 162–173, January 2006
How to Cite
Traverse-Glehen, A., Felman, P., Callet-Bauchu, E., Gazzo, S., Baseggio, L., Bryon, P. A., Thieblemont, C., Coiffier, B., Salles, G. and Berger, F. (2006), A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology, 48: 162–173. doi: 10.1111/j.1365-2559.2005.02309.x
- Issue published online: 20 DEC 2005
- Article first published online: 20 DEC 2005
- Date of submission 16 June 2005 Accepted for publication 2 September 2005
- marginal zone B-cell lymphoma;
- monocytoid B cell lymphoma;
- nodal lymphoma
Aims : To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL). NMZL is a recently characterized lymphoma and few series have been published.
Methods and results : The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%). Other features included peripheral blood involvement (23%), anaemia (24%), thrombocytopenia (10%) and presence of serum M component (33%), while the previously reported association with hepatitis C virus and cryoglobulinaemia was not found. Relapses were frequent but the majority of patients receiving chemotherapy had a good initial response. Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL). Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%). Plasmacytoid or plasmacytic differentiation was a very common feature (61%). Large cells and a high mitotic count were also frequent (57%).
Conclusion : NMZL can be distinguished from splenic MZL and extranodal MZL by its aggressive morphology and disseminated disease at presentation.